AIM ImmunoTech CEO to Participate in Virtual Panel Presentation at the 23rd Annual BioFlorida Conference on October 29th

by Barry101 | Oct 22, 2020 | Press Release, Uncategorized

OCALA, Fla. , Oct. 22, 2020 — AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech, is scheduled to participate in a virtual panel titled, “COVID-19: Progress on Treatments &...

AIM ImmunoTech Announces IRB Approval to Enroll COVID-19 ‘Long Haulers’ in the AMP-511 ME/CFS Clinical Trial of Ampligen

by Barry101 | Oct 6, 2020 | Press Release, Uncategorized

COVID-19 Patients May Continue to Experience Chronic Fatigue-Like SymptomsOCALA, Fla., Oct. 06, 2020 — AIM ImmunoTech Inc. (NYSE American: AIM) is pleased to announce that it has received Institutional Review Board (IRB) approval for the expansion of the AMP-511...

AIM ImmunoTech Receives Statistically Significant Positive Survival Results in Pancreatic Cancer from Erasmus University Medical Center, Rotterdam, Netherlands

by Barry101 | Sep 22, 2020 | Press Release, Uncategorized

Median survival approximately two-fold higher in Ampligen arm compared to historical controls; AIM to seek FDA Fast Track designation and orphan drug status in late stage pancreatic cancer OCALA, FL / September 22, 2020 / AIM ImmunoTech Inc. (NYSE American:AIM) today...

AIM ImmunoTech Highlights Start of Recruitment in Roswell Park Clinical Trial Incorporating Ampligen in the Treatment of Cancer Patients with Mild or Moderate COVID-19

by Barry101 | Sep 16, 2020 | Press Release, Uncategorized

OCALA, FL / September 16, 2020 / AIM ImmunoTech Inc. (NYSE American:AIM) today announced that recruitment has begun in Roswell Park Comprehensive Cancer Center’s Phase 1/2a clinical study of the effectiveness of rintatolimod (Ampligen) in combination with...

AIM ImmunoTech to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14th

by Barry101 | Sep 10, 2020 | Press Release, Uncategorized

OCALA, FL / September 10, 2020 / AIM ImmunoTech Inc. (NYSE American:AIM) today announced that the company will be presenting at the H.C. Wainwright Annual Global Investment Conference, being held virtually on September 14-16, 2020. Thomas K. Equels, Chief Executive...

AIM ImmunoTech CEO to Participate in Virtual Panel: ‘New Approaches to COVID-19: Hidden Breakthroughs,’ on Thursday, September 10th

by Barry101 | Sep 8, 2020 | Press Release, Uncategorized

OCALA, FL / September 8, 2020 / AIM ImmunoTech Inc. (NYSE American:AIM), today announced that Thomas K. Equels, CEO of AIM ImmunoTech, will participate in a virtual panel titled, "New Approaches to COVID-19: Hidden Breakthroughs," being held on Thursday,...